JPRN-UMIN000007488招募中2 期
To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma - To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma
ippon medical school0 个研究点目标入组 100 人开始时间: 2012年3月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.History of malignant tumor 2.Occlusion of the main trunk or first branch of Portal vein 3.T-Bil>3.0mg/dL 4.History of interstitial pneumonitis 5.History of thromboembolism 6.Severe hypertention 7.Leukocytopenia or Thrombocytopenia
研究者
相似试验
招募中
不适用
Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectivenesshepatocellular carcinomaJPRN-UMIN000005847Kyoto university hospital50
招募中
不适用
ew assessment of therapeutic response to sorafenib for advanced hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000017953Saga-Ken Medical Centre Koseikan40
进行中（未招募）
不适用
Assessment of an association of capecitabine and sorafenib in advanced pretreated colorectal cancerEUCTR2010-023695-91-BEInstitut Jules Bordet
招募中
不适用
Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study)Hepatocellular carcinomaJPRN-UMIN000006475Kagoshima University Medical and Dental Hospital70
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159